DE69434931D1 - Methode zur selektiven inaktivierung der viralen replication - Google Patents

Methode zur selektiven inaktivierung der viralen replication

Info

Publication number
DE69434931D1
DE69434931D1 DE69434931T DE69434931T DE69434931D1 DE 69434931 D1 DE69434931 D1 DE 69434931D1 DE 69434931 T DE69434931 T DE 69434931T DE 69434931 T DE69434931 T DE 69434931T DE 69434931 D1 DE69434931 D1 DE 69434931D1
Authority
DE
Germany
Prior art keywords
virus
viral replication
rna
agent
selective inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434931T
Other languages
English (en)
Other versions
DE69434931T2 (de
Inventor
Vincent J Miles
Michael B Mathews
Michael G Katze
Gary Witherell
Julia C Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of DE69434931D1 publication Critical patent/DE69434931D1/de
Application granted granted Critical
Publication of DE69434931T2 publication Critical patent/DE69434931T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69434931T 1993-04-02 1994-04-01 Methode zur selektiven inaktivierung der viralen replication Expired - Lifetime DE69434931T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4202493A 1993-04-02 1993-04-02
US42024 1993-04-02
PCT/US1994/003623 WO1994023041A2 (en) 1993-04-02 1994-04-01 Method for selective inactivation of viral replication

Publications (2)

Publication Number Publication Date
DE69434931D1 true DE69434931D1 (de) 2007-04-12
DE69434931T2 DE69434931T2 (de) 2007-11-22

Family

ID=21919634

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434931T Expired - Lifetime DE69434931T2 (de) 1993-04-02 1994-04-01 Methode zur selektiven inaktivierung der viralen replication

Country Status (9)

Country Link
US (2) US5738985A (de)
EP (1) EP0693126B9 (de)
JP (2) JP3901726B2 (de)
AT (1) ATE355380T1 (de)
AU (1) AU6497694A (de)
CA (1) CA2159639A1 (de)
DE (1) DE69434931T2 (de)
HK (1) HK1009980A1 (de)
WO (1) WO1994023041A2 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
US6627610B1 (en) 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
US6824976B1 (en) 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
CA2172824A1 (en) * 1993-10-25 1995-05-04 Charles M. Moehle Methods for screening for antimycotics
US5750394A (en) * 1994-05-20 1998-05-12 The Mount Sinai Medical Center Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
GB9420735D0 (en) * 1994-10-14 1994-11-30 Karobio Ab Reporter cell line
US6503703B1 (en) 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
AU742243B2 (en) * 1996-04-15 2001-12-20 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
PL335721A1 (en) * 1997-03-05 2000-05-08 Ribogene Novel methods of screening serving the purpose of identifying the factors of selective hepatitis c virus replication inhibition
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1189899A (en) * 1997-10-16 1999-05-03 Temple University - Of The Commonwealth System Of Higher Education Inhibition of human immunodeficiency virus (hiv-1) replication
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US7019195B1 (en) * 1998-05-26 2006-03-28 Syngenta Participations Ag Method for conferring resistance or tolerance aganist furovirus, potyvirus, tospovirus, and cucomovirus to plant cells
GB9820025D0 (en) * 1998-09-14 1998-11-04 Pfizer Ltd Assay
CA2280276A1 (en) * 1998-09-14 2000-03-14 Pfizer Inc. Assay for detecting modulators of serine/threonine phosphatase activity
US6562571B1 (en) 1999-05-25 2003-05-13 University Of Rochester Human heme-regulated initiation factor 2-α kinase
US6448007B1 (en) * 1999-07-02 2002-09-10 Message Pharmaceuticals Functional genomic screen for post-transcriptional 5′ and 3′ regulatory elements
US6586411B1 (en) * 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US6632800B1 (en) 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
US7482425B2 (en) * 1999-08-26 2009-01-27 Amylin Pharmaceuticals, Inc. Compositions for lipid matrix-assisted chemical ligation
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
CA2386270A1 (en) * 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6867036B1 (en) 1999-11-23 2005-03-15 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
WO2001051183A1 (en) * 2000-01-07 2001-07-19 Proteros, Llc. Enhanced faraday cup for diagnostic measurements in an ion implanter
WO2001084155A1 (en) 2000-04-28 2001-11-08 Message Pharmaceuticals, Inc. Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1176196A1 (de) * 2000-07-24 2002-01-30 Message Pharmaceuticals, Inc. Funktionalle genomische Selektion für post-transkriptionale 5' und 3' Regulationselemente
KR100408844B1 (ko) * 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
FR2815358A1 (fr) * 2000-10-17 2002-04-19 Parteurop Dev Polypeptides inhibiteurs de l'ires du virus de l'hepatite c et procede de criblage desdits polypeptides
US6420107B1 (en) * 2001-07-24 2002-07-16 University Of North Dakota Assay for identifying anti-viral agents specific for protein-coated double-stranded DNA viruses
DE10143106C1 (de) * 2001-09-03 2002-10-10 Artus Ges Fuer Molekularbiolog Vermehrung von Ribonukleinsäuren
US7063946B2 (en) * 2001-09-10 2006-06-20 Meso Scale Technologies, Llc. Methods, reagents, kits and apparatus for protein function analysis
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
US7968086B2 (en) * 2001-11-26 2011-06-28 Duke University Genetically stable enterovirus expression vector with replaced stem loop VI
US20030143247A1 (en) * 2002-01-30 2003-07-31 Robertson Hugh D. Antiviral compositions and methods for identification and use
WO2003064461A1 (en) * 2002-02-01 2003-08-07 Immunemed, Inc. Novel anti-viral vsf protein and hybridoma producing the same
US20030219723A1 (en) * 2002-05-20 2003-11-27 Lu Henry H. Compositions and methods for screening and identifying anti-HCV agents
AU2003298579A1 (en) * 2002-09-13 2004-04-19 Smithkline Beecham Corporation A set of ubiquitous cellular proteins involved in viral life cycle
US6821744B2 (en) 2002-10-29 2004-11-23 Roche Diagnostics Operations, Inc. Method, assay, and kit for quantifying HIV protease inhibitors
FR2848572B1 (fr) * 2002-12-12 2005-12-09 Univ Joseph Fourier Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices
WO2004076629A2 (en) * 2003-02-27 2004-09-10 Nucleonics Inc. METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES
AU2004263124B2 (en) * 2003-08-07 2009-01-15 Avi Biopharma, Inc. Sense antiviral compound and method for treating ssRNA viral infection
US20050164167A1 (en) * 2004-01-28 2005-07-28 Buscher Benjamin A. Method of discovery and development of broad-spectrum antiviral drugs
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
TWI286574B (en) * 2004-07-27 2007-09-11 Univ Chung Yuan Christian Use of bicistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation
US20080242734A1 (en) * 2004-08-06 2008-10-02 Chung Yuan Christian University Use of Biocistronic DNA Constructs for Identifying Compounds that Inhibit IRES-Dependent Translation
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2006121468A1 (en) * 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
BRPI0607769A2 (pt) * 2005-02-28 2009-10-06 Genelabs Tech Inc pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
AR056327A1 (es) * 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales
US20060293320A1 (en) * 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
US8524676B2 (en) * 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
CA2621964A1 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
WO2007070600A2 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
EP1976829A2 (de) * 2005-12-12 2008-10-08 Genelabs Technologies, Inc. N-(6-gliedriger aromatischer ring)-amidoverbindungen mit antiviraler wirkung
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
CN101356652B (zh) * 2006-06-02 2012-04-18 日本财团法人高知县产业振兴中心 包括由氧化锌构成的氧化物半导体薄膜层的半导体器件及其制造方法
CN101528741A (zh) * 2006-07-20 2009-09-09 健亚生物科技公司 多环病毒抑制剂
US7598040B2 (en) * 2006-11-22 2009-10-06 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
WO2008097866A2 (en) 2007-02-02 2008-08-14 Baylor Research Institute Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
TWI422594B (zh) * 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
EP2187883A2 (de) * 2007-08-10 2010-05-26 Genelabs Technologies, Inc. Stickstoffhaltige bicyclische chemische entitäten zur behandlung von virusinfektionen
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
US20100291032A1 (en) * 2007-09-14 2010-11-18 Trana Discovery Compositions and methods for the identification of inhibitors of retroviral infection
US8695094B2 (en) * 2008-06-24 2014-04-08 International Business Machines Corporation Detecting secondary infections in virus scanning
WO2010036795A2 (en) * 2008-09-29 2010-04-01 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US8277651B2 (en) 2009-03-13 2012-10-02 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
EP3199634A1 (de) 2009-11-13 2017-08-02 Sarepta Therapeutics, Inc. Antivirale antisense-verbindung und verfahren zur behandlung von influenzavirusinfektion
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
CN103209963A (zh) 2010-07-02 2013-07-17 吉里德科学公司 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
US9040690B2 (en) 2010-07-22 2015-05-26 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
CA2847413C (en) 2010-09-02 2018-05-22 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
EP2658857B1 (de) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
MD20140063A2 (ro) 2012-04-20 2014-12-31 Gilead Sciences, Inc. Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
TWI448538B (zh) 2012-10-23 2014-08-11 Ind Tech Res Inst 螢光材料與紫外光發光裝置
CN106659774A (zh) 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
CN107636464B (zh) 2015-05-06 2020-08-11 宝洁公司 口腔中微生物毒力因子的解毒
GB202016650D0 (en) * 2020-10-20 2020-12-02 Primer Design Ltd Kit and method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE75483T1 (de) * 1981-10-23 1992-05-15 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
GB8911555D0 (en) * 1989-05-19 1989-07-05 Inglis Stephen C Ribosomal frame-shift signals and uses
ATE154947T1 (de) * 1990-08-16 1997-07-15 Isis Pharmaceuticals Inc Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen
JP3378962B2 (ja) * 1991-08-07 2003-02-17 アンダースン，ダブリュー．，フレンチ 内部リボソームエントリー部位を含むレトロウイルスベクター

Also Published As

Publication number Publication date
US6156496A (en) 2000-12-05
WO1994023041A3 (en) 1995-01-05
WO1994023041A2 (en) 1994-10-13
JPH08509213A (ja) 1996-10-01
EP0693126B1 (de) 2007-02-28
ATE355380T1 (de) 2006-03-15
CA2159639A1 (en) 1994-10-13
DE69434931T2 (de) 2007-11-22
EP0693126A1 (de) 1996-01-24
JP2007075116A (ja) 2007-03-29
HK1009980A1 (en) 1999-06-11
EP0693126B9 (de) 2007-09-12
US5738985A (en) 1998-04-14
AU6497694A (en) 1994-10-24
JP3901726B2 (ja) 2007-04-04

Similar Documents

Publication Publication Date Title
DE69434931D1 (de) Methode zur selektiven inaktivierung der viralen replication
DK1526172T3 (da) Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
DE50214416D1 (de) Vermehrung von viren in zellkultur
DE3486160T2 (de) Modifizierte lebende Pseudo-Rabies-Viren, diese enthaltende Impfstoffe gegen Pseudo-Rabies, Verfahren zur Herstellung und Verfahren zur Verwendung derselben.
WO2005042767A3 (en) Compositions and methods for detecting severe acute respiratory syndrome coronavirus
DK0904351T3 (da) Dyreceller og fremgangsmåder til replikationen af influenzavirus
SE8405133L (sv) Anti-viralt medel
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
DE69128077T2 (de) Nuklein-säure amplifikation mit dns abhängigen rns polymerasen aktivität von rns-replikasen
DK1126859T3 (da) Blodleukocyt-aferese til behandling af HIV
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
DK0832211T3 (da) Oligonucleotider, der er specifikke for hepatitis B-virus.
ES2123048T3 (es) Analogos de nucleosidos antiviricos.
DE59103696D1 (de) Biomasse zur produktion von virus/virusantigen.
DE58904809D1 (de) Plasma-roentgenroehre, insbesondere zur roentgen-vorionisierung von gaslasern, und verwendung als elektronenkanone.
DE69703672T2 (de) Antivirusverbindungen
DE60117561D1 (de) Verbesserte replikation von hcv rna
ATE255594T1 (de) Hepatitis b inhibitoren
EP0593291A3 (de) Nichtstrukturales Protein des Hepatitis C-Virus, sowie diagnostisches Verfahren und Testsatz.
WO2000015210A3 (en) Use of mycophenol acid and its derivatives for the treatment of virus diseases
EA200101228A1 (ru) ИСПОЛЬЗОВАНИЕ АНТИТЕЛ, УЗНАЮЩИХ РЕЦЕПТОР ИНТЕРЛЕЙКИН-2, ДЛЯ ПРЕДУПРЕЖДЕНИЯ И/ИЛИ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСАМИ СПИДа
DE59410140D1 (de) Rinderovarzellinie (FROv) zur Virusvermehrung
FR2621816B1 (fr) Application antivirale des ologonucleotides

Legal Events

Date Code Title Description
8364 No opposition during term of opposition